Mycio Wealth Partners LLC boosted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 7.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,344 shares of the medical research company’s stock after acquiring an additional 289 shares during the period. Mycio Wealth Partners LLC’s holdings in Amgen were worth $801,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Norges Bank purchased a new position in Amgen during the 4th quarter valued at about $1,283,248,000. Thoroughbred Financial Services LLC lifted its position in Amgen by 19,447.3% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock valued at $180,539,000 after acquiring an additional 1,796,156 shares during the period. Ellis Investment Partners LLC lifted its position in Amgen by 18,906.7% during the 1st quarter. Ellis Investment Partners LLC now owns 605,934 shares of the medical research company’s stock valued at $605,000 after acquiring an additional 602,746 shares during the period. Geode Capital Management LLC increased its stake in Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after purchasing an additional 482,760 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in Amgen by 37.3% during the 2nd quarter. First Trust Advisors LP now owns 1,196,708 shares of the medical research company’s stock valued at $220,529,000 after purchasing an additional 325,404 shares in the last quarter. 78.01% of the stock is owned by institutional investors.
In other Amgen news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total transaction of $351,360.00. Following the transaction, the director now directly owns 16,219 shares in the company, valued at approximately $2,849,353.92. The disclosure for this sale can be found here. Insiders have sold 4,425 shares of company stock worth $804,312 in the last ninety days. Insiders own 0.25% of the company’s stock.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating the consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter in the previous year, the firm earned $3.83 earnings per share. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. Equities analysts forecast that Amgen, Inc. will post 14.25 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be issued a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend is Wednesday, August 14th. Amgen’s dividend payout ratio is currently 40.28%.
A number of research firms have weighed in on AMGN. Morgan Stanley reduced their price objective on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. BMO Capital Markets set a $230.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Wednesday, July 31st. Mizuho lowered shares of Amgen from a “buy” rating to a “neutral” rating and raised their price objective for the company from $208.00 to $212.00 in a research note on Monday. They noted that the move was a valuation call. Wells Fargo & Co raised their price objective on shares of Amgen from $197.00 to $202.00 and gave the company a “market perform” rating in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Amgen currently has a consensus rating of “Buy” and a consensus target price of $212.94.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: New Google Finance Tool and Screening Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.